Reporte zur Charge UI433AA

Symptomtext

experienced reactivity (IgE type); Initial information received on 21-Mar-2022 regarding an unsolicited valid serious case received from a pharmacist via call center. This case involves an unknown age and unknown gender patient who experienced reactivity (ige type) while receiving vaccine influenza quadrival a-b vaccine [Fluzone qiv]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Latex allergy. On an unknown date, the patient received a dose of suspect influenza quadrival a-b vaccine [fluzone qiv].(batch lot UI433AA;expiry date :23-Sep-2015)(unknown dosage strength, route of administration, formulation) in unknown administration site. for immunization. On an unknown date the patient developed a serious experienced reactivity (ige type) (Type I hypersensitivity ) (unknown latency) following the administration of influenza quadrival a-b vaccine. This event was assessed as medically significant. Action taken : not applicable. It was not reported if the patient received a corrective treatment for the event (experienced reactivity (IgE type)). At time of reporting, the outcome was Unknown for the event (experienced reactivity (IgE type).; Sender's Comments: Sanofi Company Comment dated (24-Mar-2022) This case involves an unknown age and unknown gender patient who experienced reactivity (ige type) while receiving vaccine influenza quadrival a-b vaccineAdditional information regarding condition at the time of vaccination, medical history, concomitant disease or risk factor and other lab data excluding other predisposing etiologies would be needed for complete assessment of the case. Based upon the reported information, the role of vaccine cannot be assessed.